Company Profile

Icosavax, Inc. is a biopharmaceutical company. The Company uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on life-threatening respiratory diseases. Its VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens. Its pipeline includes vaccine candidates targeting viral causes of pneumonia. It is developing these candidates for older adults, a patient population with high unmet need. Its lead vaccine candidate, IVX-A12, is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV). It is also developing additional vaccine candidates as part of its strategy to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults, including influenza and SARS-CoV-2.

Employees

Sector

Biotechnology & Medical Research

More about the company

19/02/24	Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index	CI
19/02/24	Icosavax, Inc.(NasdaqGS:ICVX) dropped from S&P TMI Index	CI
19/02/24	Europe lacks direction on quiet Monday	AN
19/02/24	AstraZeneca Completes $1 Billion Acquisition of Icosavax	MT
19/02/24	AstraZeneca: successfully completes acquisition of Icosavax
19/02/24	AstraZeneca completes USD1.1 billion acquisition of Icosavax	AN
18/02/24	AstraZeneca PLC completed the acquisition of Icosavax, Inc. from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management Company Limited and others.	CI
18/02/24	Icosavax, Inc.(NasdaqGS:ICVX) dropped from S&P Global BMI Index	CI
26/01/24	Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Biotechnology Index	CI
08/01/24	Icosavax Insider Sold Shares Worth $1,670,460, According to a Recent SEC Filing	MT
02/01/24	Guggenheim Downgrades Icosavax to Neutral From Buy	MT
18/12/23	Icosavax, Inc.(NasdaqGS:ICVX) added to NASDAQ Biotechnology Index	CI
13/12/23	FTSE 100 Edges Higher as European Markets Remain Cautious Ahead of Rate Calls	DJ

02/01/24	Guggenheim Downgrades Icosavax to Neutral From Buy	MT
12/12/23	Jefferies Downgrades Icosavax to Hold From Buy, Cuts Price Target to $15.50 From $30	MT
12/12/23	William Blair Downgrades Icosavax to Market Perform From Outperform	MT
17/11/23	Guggenheim Starts Icosavax With Buy Rating, $28 Price Target	MT
24/05/23	Oppenheimer Adjusts Icosavax Price Target to $25 From $27, Maintains Outperform Rating	MT

20/02/24	AstraZeneca - Acquisition of Icosavax Completed	AQ
01/02/24	Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm	PR
29/12/23	ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX	BU
15/12/23	ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX	BU
13/12/23	SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Icosavax; Is the Deal in the Best Interest of Shareholders?	BU

19/02/24	AstraZeneca : rachète la biotech américaine Icosavax, spécialiste des vaccins
19/02/24	AstraZeneca : finalise avec succès l'acquisition de Icosavax
08/02/24	Astrazeneca: bénéfice 2023 dopé malgré la perte des recettes Covid
13/12/23	MORNING BRIEFING - USA/Asien
13/12/23	MORNING BRIEFING - Deutschland/Europa

Manager	Title	Age	Since
Thomas Russo DFI	Director of Finance/CFO	54	31/05/2021
Jennifer Raymond CTO	Chief Tech/Sci/R&D Officer	-	-
Niranjan Kanesa-thasan CTO	Chief Tech/Sci/R&D Officer	66	31/08/2018

Icosavax, Inc. Share Price

Stocks

ICVX

US45114M1099

Biotechnology & Medical Research

Latest news : Icosavax, Inc.

Analysts' recommendations: Icosavax, Inc.

Press Releases: Icosavax, Inc.

News in other languages: Icosavax, Inc.

Quotes and Performance

Managers and Directors: Icosavax, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
18/02/24	James Wassil	Tender	Director	72,643	0.1450%
18/02/24	RA Capital Management LP	Tender	Company	6,008,386	11.9951%
18/02/24	Cassia Cearley	Tender	Executive/Senior Manager	831,638	1.6603%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ICOSAVAX, INC.	-0.91%	-0.13%	-	-	778M
LONZA GROUP AG	+1.70%	+7.41%	+3.12%	+8.46%	49.92B
REVOLUTION MEDICINES, INC.	+0.92%	+3.93%	+399.71%	+605.33%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+8.32%	+26.06%	-6.35%	34.55B
BEONE MEDICINES AG	+2.38%	+6.35%	+21.25%	+64.58%	33.09B
CELLTRION, INC.	+3.96%	+10.67%	+11.89%	+38.86%	27.51B
ASCENDIS PHARMA A/S	+2.51%	+5.27%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+5.79%	+73.44%	+133.27%	15.92B
EUROFINS SCIENTIFIC SE	+0.32%	+0.58%	+13.67%	+19.09%	13.86B
IONIS PHARMACEUTICALS, INC.	+3.30%	+0.76%	+90.23%	+99.12%	13.52B
Average	+1.86%	+5.82%	+79.92%	+120.30%	27.3B
Weighted average by Cap.	+2.06%	+6.53%	+90.75%	+137.74%